Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468396) titled 'A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer' on March 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Gan & Lee Pharmaceuticals.

Condition: Prostate Cancer

Intervention: Drug: GLR2037

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 30, 2026

Target Sample Size: 65

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07468396

Disclaimer: Curated by HT Syndication....